Shares of Globus Medical (NYSE:GMED) plummeted 14.44% in after-hours trading on Thursday following the release of the company's first-quarter 2025 financial results, which fell short of analyst expectations.

The medical device company reported adjusted earnings per share (EPS) of $0.68, missing the analyst consensus estimate of $0.74 by 8.11%. This represents a 5.56% decrease compared to the same period last year when the company reported earnings of $0.72 per share. Globus Medical's quarterly sales also disappointed, coming in at $598.12 million, 4.44% below the analyst consensus estimate of $625.90 million. The reported sales figure marks a 1.41% decrease from the $606.67 million recorded in the same quarter of the previous year.

The company's net income for the first quarter stood at $75.5 million, with a reported EPS of $0.54. The significant gap between Wall Street's expectations and Globus Medical's actual performance appears to have shaken investor confidence, leading to the sharp decline in stock price during after-hours trading. As the medical device industry faces ongoing challenges, investors will be closely watching Globus Medical's future guidance and strategies to address this underperformance.